Wilson's disease presenting with arthralgia: a case report.

Metabolic homeostasis relies on the precise regulation of trace elements. Essential micronutrients like copper must be available for enzymatic functions. However, they must not reach toxic concentrations. Wilson’s disease (WD) is a rare autosomal recessive disorder that disrupts this balance. It is caused by mutations in the ATP7B gene. This mutation impairs the liver's ability to transport and excrete excess copper. Consequently, the metal undergoes progressive, multisystem accumulation in vital organs.

While clinicians traditionally look for hepatic (liver-related) or neuropsychiatric (brain and behavior-related) symptoms, the clinical landscape of Wilson's disease is notoriously heterogeneous. This diversity often masks the disease's true nature. Accumulation can manifest in unexpected ways. This case report highlights a critical diagnostic gap. Wilson's disease can present initially as arthralgia (unexplained joint pain). This occurs instead of the more common signs of liver or neurological distress.

The diagnostic shadow of atypical symptoms

In the standard clinical framework, Wilson's disease is categorized by its predominant manifestations. Most patients present with liver dysfunction, such as jaundice or cirrhosis. Others show neurological disturbances like tremors or gait instability. Because these "classic" presentations are well-documented, clinicians often rely on mental heuristics. These are cognitive shortcuts or rules of thumb used to make quick decisions.

This reliance creates a significant blind spot. When a patient presents with symptoms outside the hepatic or neurological norm, the risk of misdiagnosis increases. The literature suggests that the average time to a Wilson's disease diagnosis often exceeds two years. This delay is dangerous. Untreated copper accumulation can lead to irreversible neurological damage or even death. The paper argues that current diagnostic approaches fail to account for "atypical" entry points. Osteoarticular (bone and joint) symptoms can lead doctors toward incorrect paths. They might mistakenly treat the patient for inflammatory conditions like rheumatoid arthritis.

Deciphering the copper accumulation mechanism

The pathology of Wilson's disease follows a predictable biochemical cascade. This cascade is triggered by a single genetic failure. The authors describe the mechanism through the following progression:

1. Genetic Mutation: A homozygous missense variant (a change in a single DNA building block that results in a different amino acid) occurs in the ATP7B gene. In this case, the mutation was c.2975C > T (p.Pro992Leu).
2. Transport Failure: The mutated ATP7B protein fails to facilitate proper copper transport. Specifically, it cannot move copper from liver cells into the bile for excretion.
3. Systemic Accumulation: Because the copper cannot be excreted, it builds up within the hepatocytes (liver cells). It eventually spills over into the bloodstream and other tissues.
4. Tissue Toxicity: Excess copper deposits in various organs. In this patient, deposition caused both hepatic dysfunction and localized inflammation in the joints.

To confirm this mechanism, the researchers used the Leipzig scoring system. This is a validated tool used to categorize the probability of Wilson's disease based on clinical and biochemical markers. The patient achieved a total score of 10. This score represents a definitive threshold for diagnosis.

Biochemical evidence of metabolic failure

The authors provide a detailed quantitative profile of the patient's metabolic state. The laboratory results reveal a profound disruption of copper homeostasis.

The most striking metric is the serum ceruloplasmin level. It was recorded at 0.042 g/L. This is significantly below the standard reference range of 190–670 mg/L. Ceruloplasmin is a protein that carries copper in the blood. Its depletion is a hallmark of WD because the defective ATP7B protein disrupts the normal copper-loading process. Simultaneously, the 24-hour urinary copper excretion was highly elevated at 166.4 µg/24 h. This is much higher than the normal range of 15–30 µg/24 h. This indicates that while the liver cannot excrete copper into the bile, the kidneys are attempting to clear the excess.

Liver dysfunction was also evident in several biochemical markers: * AST (Aspartate Aminotransferase): 110 U/L (Reference: <40 U/L). This elevation indicates active liver cell injury. * ALT (Alanine Aminotransferase): 59 U/L (Reference: <49 U/L). This confirms ongoing hepatic stress. * Total Bilirubin: 33.0 µmol/L (Reference: 5–23 µmol/L). High levels suggest impaired liver processing of waste. * Total Bile Acids (TBA): 43.5 µmol/L (Reference: 0–10 µmol/L). This reflects significant cholestatic (bile flow obstruction) dysfunction.

The intervention was highly effective. Doctors initiated a low-copper diet and pharmacologic therapy. They used penicillamine, which is a copper-chelating agent (a substance that binds to metals to help remove them). They also used zinc. By the one-month follow-up, total bile acids had dropped to 21.6 µmol/L. Furthermore, the patient's joint pain had completely resolved.

Limitations of the clinical snapshot

This case provides a compelling argument for expanded diagnostic considerations. However, it possesses inherent limitations. As a single case report, the findings cannot be generalized to all pediatric patients. We cannot determine exactly how frequently arthralgia serves as the primary symptom.

The study also does not address the long-term prognosis for joint health. While the pain resolved after reducing copper, the MRI showed abnormal signals. Specifically, these were seen in the distal metaphysis and epiphysis (the ends of long bones) of the tibia and fibula. The paper does not clarify if these will lead to permanent structural deformities. Finally, the study focuses on identification. It does not explore the difficulties of maintaining long-term compliance with intensive copper-chelating regimens in children.

The clinical verdict

The evidence presented by Li and Wen warrants a shift in clinical approach. If a child presents with unexplained, recurrent arthralgia, doctors must take notice. This is especially true if the child has even mild elevations in liver enzymes. In such cases, Wilson's disease must move up the list of differential diagnoses. The transition from a Leipzig score of 10 to complete symptomatic resolution proves a vital point. Early recognition is not just a diagnostic exercise. It is a life-saving intervention. Practitioners should not let atypical symptoms mask a classic metabolic catastrophe.